Cadrenal Therapeutics, Inc. (CVKD) Price & Analysis

Compare

361 Followers

CVKD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.89 - $22.90

Previous CloseN/A

Volume16.20K

Average Volume (3M)30.93K

Market Cap

$27.20M

Enterprise Value$18.07M

Total Cash (Recent Filing)$5.57M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.31

Next Earnings

Nov 06, 2025

EPS Estimate

-1.55

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.87

Shares Outstanding2,046,854

10 Day Avg. Volume33,837

30 Day Avg. Volume30,925

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.66

Enterprise Value/Revenue8.47K

Enterprise Value/Gross Profit-3.44K

Enterprise Value/Ebitda-1.28

Forecast

1Y Price Target

$45.00

Price Target Upside238.60% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentThe trial will test tecarfarin efficacy in reducing mortality and cardiac events during the ultra-high risk period after starting dialysis.

Strategic PartnershipCadrenal announced a development agreement with Abbott to develop Tecarfarin in patients with Abbott’s HeartMate3 LVAD.

Bears Say

Financial ConcernsCadrenal ended the quarter with $7.3 million, which is highlighted as a significant concern, as additional funding will be necessary to support ongoing operations.

Regulatory ChallengesThe FDA meeting led to an agreement that demonstrating superiority in the trial would not be feasible, leading to alignment on a non-inferiority design instead.

Cadrenal Therapeutics, Inc. News

Cadrenal Therapeutics reports Q2 EPS ($1.87), consensus ($1.77)

“We continue to advance our goal of developing transformative therapeutics to address the gaps in current anticoagulation therapy...

19d ago

CVKD

Cadrenal Therapeutics announces trial plans for tecarfarin

Cadrenal Therapeutics (CVKD) announced clinical trial initiation plans for its lead late-stage drug candidate, tecarfarin, in patients with...

25d ago

CVKD

Cadrenal Therapeutics Advances Tecarfarin Development

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has released its Q2 earnings. Here is a breakdown of the information...

18d ago

CVKD

Cadrenal Therapeutics to Initiate Tecarfarin Clinical Trial

The latest announcement is out from Cadrenal Therapeutics, Inc. ( ($CVKD) ). On August 5, 2025, Cadrenal Therapeutics...

25d ago

CVKD

Cadrenal Therapeutics Director Resignation Announced

Cadrenal Therapeutics, Inc. ( ($CVKD) ) just unveiled an announcement. On July 15, 2025, Robert Lisicki resigned from...

1M ago

CVKD

Positive Outlook for Cadrenal Therapeutics, Inc. Amid Strategic Developments and FDA Trial Milestone

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Cadrenal Therapeutics, Inc. (CVKD – Research Report),...

4M ago

CVKD

Cadrenal Therapeutics Reports Increased Losses Amid R&D Expansion

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

CVKD

Cadrenal Therapeutics Advances Tecarfarin Development in 2024

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has released its Q4 earnings. Here is a breakdown of the information...

6M ago

CVKD

Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial

Cadrenal Therapeutics (CVKD) announced the signing of a Collaboration Agreement with Abbott (ABT) ( ABT) to support Cadrenal’s...

6M ago

ABT

CVKD

Cadrenal Therapeutics Appoints New Chief Medical Officer

Cadrenal Therapeutics, Inc. ( ($CVKD) ) just unveiled an announcement. On February 4, 2025, Cadrenal Therapeutics, Inc. appointed...

7M ago

CVKD

Cadrenal Therapeutics CMO Douglas Losordo departs, James Ferguson succeeds

Cadrenal Therapeutics (CVKD) announced a leadership transition appointing James Ferguson as its new chief medical officer, effective immediately....

7M ago

CVKD

MTNB

Cadrenal Therapeutics to initiate Phase 3 clinical trial for tecarfarin in 2025

Cadrenal Therapeutics (CVKD) recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug...

8M ago

CVKD

Cadrenal Therapeutics files to sell 590K shares of common stock for holders

16:09 EST Cadrenal Therapeutics (CVKD) files to sell 590K shares of common stock for holders Published first on...

10M ago

CVKD

Cadrenal Therapeutics target adjusted to $32 from $3 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Cadrenal Therapeutics (CVKD) to $32 from $3 and keeps a...

10M ago

CVKD

CVKD FAQ

What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?

Cadrenal Therapeutics, Inc. lowest stock price was $6.89 and its highest was $22.90 in the past 12 months.

What is Cadrenal Therapeutics, Inc.’s market cap?

Cadrenal Therapeutics, Inc.’s market cap is $27.20M.

When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?

Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 68 days.

How were Cadrenal Therapeutics, Inc.’s earnings last quarter?

Cadrenal Therapeutics, Inc. released its earnings results on Aug 11, 2025. The company reported -$1.87 earnings per share for the quarter, missing the consensus estimate of -$1.775 by -$0.095.

Is Cadrenal Therapeutics, Inc. overvalued?

According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cadrenal Therapeutics, Inc. pay dividends?

Cadrenal Therapeutics, Inc. does not currently pay dividends.

What is Cadrenal Therapeutics, Inc.’s EPS estimate?

Cadrenal Therapeutics, Inc.’s EPS estimate is -1.55.

How many shares outstanding does Cadrenal Therapeutics, Inc. have?

Cadrenal Therapeutics, Inc. has 2,046,854 shares outstanding.

What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?

Cadrenal Therapeutics, Inc. reported an EPS of -$1.87 in its last earnings report, missing expectations of -$1.775. Following the earnings report the stock price went down -1.883%.

Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?

Currently, no hedge funds are holding shares in CVKD

Cadrenal Therapeutics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-340.31%

Trailing 12-Months

Asset Growth

9.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Cadrenal Therapeutics, Inc. (CVKD) Earnings & Revenues

Historic Earnings Reports

CVKD Stock 12 Month Forecast

Average Price Target

$45.00

▲(238.60% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","46":"$46","15.25":"$15.25","25.5":"$25.5","35.75":"$35.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,15.25,25.5,35.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.33,12.996923076923077,15.663846153846155,18.33076923076923,20.997692307692308,23.664615384615384,26.331538461538464,28.99846153846154,31.665384615384617,34.332307692307694,36.99923076923077,39.66615384615385,42.33307692307692,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.33,12.996923076923077,15.663846153846155,18.33076923076923,20.997692307692308,23.664615384615384,26.331538461538464,28.99846153846154,31.665384615384617,34.332307692307694,36.99923076923077,39.66615384615385,42.33307692307692,{"y":45,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.33,12.996923076923077,15.663846153846155,18.33076923076923,20.997692307692308,23.664615384615384,26.331538461538464,28.99846153846154,31.665384615384617,34.332307692307694,36.99923076923077,39.66615384615385,42.33307692307692,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.5,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.39,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.28,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.82,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.44,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.19,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.49,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.46,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.5,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >